Free Trial
NASDAQ:SONN

Sonnet BioTherapeutics Q1 2024 Earnings Report

Sonnet BioTherapeutics logo
$3.25 -0.13 (-3.85%)
Closing price 04:00 PM Eastern
Extended Trading
$3.30 +0.04 (+1.38%)
As of 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonnet BioTherapeutics EPS Results

Actual EPS
-$2.48
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sonnet BioTherapeutics Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sonnet BioTherapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Wednesday, February 14, 2024
Conference Call Time
7:00AM ET

Sonnet BioTherapeutics Earnings Headlines

Sonnet BioTherapeutics (NASDAQ:SONN) Upgraded at Wall Street Zen
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist Ben Stein—drawing on insights from his own experience and his father’s time advising two U.S. presidents—just released a new report on how to help protect your retirement from the next major crisis.tc pixel
Sonnet Releases Virtual Investor "What This Means" Segment
See More Sonnet BioTherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sonnet BioTherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sonnet BioTherapeutics and other key companies, straight to your email.

About Sonnet BioTherapeutics

Sonnet BioTherapeutics (NASDAQ:SONN), a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

View Sonnet BioTherapeutics Profile

More Earnings Resources from MarketBeat